SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 358.12 |
| Enterprise Value ($M) | 360.28 |
| Book Value ($M) | 259.65 |
| Book Value / Share | 5.18 |
| Price / Book | 1.38 |
| NCAV ($M) | 71.66 |
| NCAV / Share | 1.43 |
| Price / NCAV | 5.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -0.36 |
| Return on Equity (ROE) | -0.58 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.69 |
| Current Ratio | 2.69 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 278.00 |
| Assets | 465.99 |
| Liabilities | 206.34 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 83.33 |
| Operating Income | -231.25 |
| Net Income | -227.10 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -173.12 |
| Cash from Investing | 103.45 |
| Cash from Financing | 92.68 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Jpmorgan Chase & Co | 7.40 | 49.41 | |
| 13G | State Street Corp | 4.40 | -16.93 | |
| 13G/A | Vanguard Group Inc | 6.02 | -31.66 | |
| 13G | BlackRock, Inc. | 11.00 | -33.40 | |
| 13G/A | Redmile Group, LLC | 9.90 | 31.42 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 128,413 | 838,788 | 15.31 | |
| 115,769 | 908,138 | 12.75 | |
| 54,656 | 348,559 | 15.68 | |
| 46,671 | 433,608 | 10.76 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| REGN – Regeneron Pharmaceuticals, Inc. | REPL – Replimune Group, Inc. |
| RGEN – Repligen Corporation | RIGL – Rigel Pharmaceuticals, Inc. |
| RLMD – Relmada Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io